RayzeBio

Executive Summary

RayzeBio is a private biopharmaceutical company headquartered in San Diego, California, pioneering the development of precision radiopharmaceutical therapies (RPTs) using actinium-225. Founded in 2020, the company has established a leadership position in actinium-based RPTs, leveraging its innovative platform to create potential first-in-class and best-in-class treatments for cancer. RayzeBio's pipeline focuses on targeted alpha therapies that deliver potent radiation directly to tumor cells, minimizing damage to healthy tissue. The company's approach addresses significant unmet medical needs across multiple oncology indications, with a particular emphasis on solid tumors that are difficult to treat with conventional modalities. Given its position at the forefront of the next wave of cancer treatment, RayzeBio is well-positioned to capitalize on the growing interest in radiopharmaceuticals. However, as a private entity with limited public disclosures, the company's near-term outlook hinges on successful clinical execution and strategic partnerships. Key upcoming milestones include initial clinical data readouts for its lead candidates and potential collaborative agreements to expand its pipeline and manufacturing capabilities. While still early-stage, RayzeBio's proprietary technology and experienced team suggest significant upside if clinical validation is achieved.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1 Data for Lead RPT Candidate45% success
• Q3 2026Strategic Partnership or Licensing Deal30% success
• Q4 2026Series B or Series C Financing Round70% success